Figures & data
Figure 1. A dynamic 18F-FDG-PET image series in the coronal plane showing the heart and the implanted bilateral human breast cancer xenografts MAS98.12 xenografts. The corresponding uptake kinetics are shown in graphs A and B, respectively, where the latter constitutes the arterial input function (AIF). Also, the results from the pharmacokinetic model fit are shown.
![Figure 1. A dynamic 18F-FDG-PET image series in the coronal plane showing the heart and the implanted bilateral human breast cancer xenografts MAS98.12 xenografts. The corresponding uptake kinetics are shown in graphs A and B, respectively, where the latter constitutes the arterial input function (AIF). Also, the results from the pharmacokinetic model fit are shown.](/cms/asset/3b4fc3aa-abca-498e-8608-1d3969057816/ionc_a_813634_f0001_b.jpg)
Figure 2. Cohort-based median time-activity curves, normalized to the AIF, for tumors at baseline and 24 and 72 hours after administration of bevacizumab.
![Figure 2. Cohort-based median time-activity curves, normalized to the AIF, for tumors at baseline and 24 and 72 hours after administration of bevacizumab.](/cms/asset/5be54439-d877-4bba-b4c9-d1895495327b/ionc_a_813634_f0002_b.gif)